NCT01701934View on ClinicalTrials.gov

Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Obstructive Pulmonary DiseaseMetabolic Syndrome
Interventions
DRUG

Roflumilast

500 mcg, oral, once daily for 6 months

DRUG

Placebo

One placebo pill daily, for 6 months

Trial Locations (5)

V6Z 1Y6

St. Paul's Hospital, Vancouver

H2W 1T8

Centre hospitalier de l'Université de Montréal, Montreal

H2X 2P4

Montreal Chest Institute, Montreal

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec, Québec

J7Z 5T3

Hôpital régional de Saint-Jérôme, Saint-Jérôme

Sponsors

Collaborators (2)

Innovair
Takeda
All Listed Sponsors
collaborator

Innovair

UNKNOWN

collaborator

Takeda

INDUSTRY

lead

Laval University

OTHER

NCT01701934 - Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter